The number of women with stage II to IVA cervical cancer treated in the US with chemotherapy more than doubled during the period 1997 to 2001.
The number of women with stage II to IVA cervical cancer treated in the United States with chemotherapy more than doubled (34%–85%), and the number treated with concurrent chemoradiation more than tripled (20%–72%), during the period 1997 to 2001, according to the findings of a recent analysis of patterns of care.
The analysis included data on more than 3,000 women with no previous diagnosis of cancer. The researchers concluded that the rapid shifts in treatment were most likely fueled by the publication of five important clinical trials in 1999 and 2000 demonstrating increased overall survival associated with chemoradiation, as well as by a Clinical Announcement distributed by the National Cancer Institute in 1999 to physicians most apt to treat the condition.
Trimble EL, Harlan LC, Gius D, et al. Patterns of care for women with cervical cancer in the United States. Cancer. 2008;113:743-749.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More